Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Qiagen N.V.    QGEN   NL0012169213

QIAGEN N.V.

(QGEN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
07/06/2020 07/07/2020 07/08/2020 07/09/2020 07/10/2020 Date
43.26(c) 43.19(c) 43.57(c) 44.55(c) 45.31(c) Last
1 790 678 538 349 853 474 1 146 109 1 530 728 Volume
+1.76% -0.16% +0.88% +2.25% +1.71% Change
More quotes
Financials (USD)
Sales 2020 1 657 M - -
Net income 2020 253 M - -
Net Debt 2020 950 M - -
P/E ratio 2020 36,4x
Yield 2020 -
Sales 2021 1 729 M - -
Net income 2021 288 M - -
Net Debt 2021 627 M - -
P/E ratio 2021 33,0x
Yield 2021 -
Capitalization 10 353 M 10 353 M -
EV / Sales 2020 6,82x
EV / Sales 2021 6,35x
Nbr of Employees 5 100
Free-Float 97,2%
More Financials
Company
Qiagen N.V. is one of the world's leaders in designing, manufacturing, and marketing chemical products for the isolation, purification, and manipulation of DNA (deoxyribonucleic acid) and RNA (ribonucleic acid). In 2019, the group developed more than 500 consumable products and automated solutions through its 35 production sites worldwide. Net sales break down geographically as follows: the United States (43.5%),... 
More about the company
Surperformance© ratings of Qiagen N.V.
Trading Rating : Investor Rating :
More Ratings
Latest news on QIAGEN N.V.
07/10QIAGEN N.V. : Release according to Article 40, Section 1 of the WpHG [the German..
EQ
07/10Qiagen shareholder Davidson Kempner says Thermo Fisher offer 'inadequate'
RE
07/10QIAGEN NV : Warburg Research reiterates its Neutral rating
MD
07/09QIAGEN N : announces preliminary results for Q2 2020
PU
07/09QIAGEN N.V. : QIAGEN announces preliminary results for Q2 2020
EQ
07/08QIAGEN N.V. : Release according to Article 40, Section 1 of the WpHG [the German..
EQ
07/03QIAGEN N.V. : Release according to Article 40, Section 1 of the WpHG [the German..
EQ
07/02Elizabeth Tallett Joins Moderna's Board of Directors
AQ
06/30QIAGEN N : shareholders approve all agenda items related to acquisition by Therm..
PU
06/24QIAGEN N.V. : Release according to Article 40, Section 1 of the WpHG [the German..
EQ
06/23QIAGEN N : provides information on potential capital gain from its minority inve..
PU
06/23QIAGEN N.V. : QIAGEN provides information on potential capital gain from its min..
EQ
06/23QIAGEN NV : Warburg Research reaffirms its Neutral rating
MD
06/22QIAGEN N : Announces Plans to Release Preliminary Q2 2020 Results
BU
06/19QIAGEN N.V. : Release according to Article 40, Section 1 of the WpHG [the German..
EQ
More news
News in other languages on QIAGEN N.V.
07/10QIAGEN N.V. : Release according to Article 40, Section 1 of the WpHG [the German..
07/10Qiagen shareholder Davidson Kempner says Thermo Fisher offer 'inadequate'
07/10Aktien Frankfurt Schluss: Anleger honorieren positive Konjunkturdaten
07/10DPA-AFX-ÜBERBLICK : UNTERNEHMEN vom 10.07.2020 - 15.15 Uhr
07/10Aktien Frankfurt: Dax profitiert von guten Konjunkturdaten aus Italien
More news
Analyst Recommendations on QIAGEN N.V.
More recommendations
Chart QIAGEN N.V.
Duration : Period :
Qiagen N.V. Technical Analysis Chart | QGEN | NL0012169213 | MarketScreener
Technical analysis trends QIAGEN N.V.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 13
Average target price 41,17 $
Last Close Price 45,31 $
Spread / Highest target 10,4%
Spread / Average Target -9,14%
Spread / Lowest Target -31,6%
EPS Revisions
Managers
NameTitle
Thierry Bernard Chief Executive Officer
Sven Håkan Björklund Chairman-Supervisory Board
Barthold Piening Senior Vice President & Head-Global Operations
Roland Sackers Chief Financial Officer & Managing Director
Metin Colpan Independent Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
QIAGEN N.V.31.80%10 353
LONZA GROUP52.43%42 546
CELLTRION, INC.79.28%36 149
SEATTLE GENETICS, INC.52.59%30 180
IQVIA HOLDINGS INC.-7.66%27 247
MODERNA, INC.220.09%24 344